Journal article
Retrospective review of intermittent and continuous infusion vancomycin for methicillin-resistant Staphylococcus aureus bacteremia
European journal of clinical pharmacology, Vol.80(1), pp.75-81
01/2024
DOI: 10.1007/s00228-023-03585-2
PMID: 37897529
Abstract
Purpose
Vancomycin is commonly administered as an intermittent infusion (IIV), although vancomycin’s stability at room temperature permits administration continuously over 24 h (CIV). At our institution, CIV has been the preferred infusion method for over 20 years due to ease of administration and simplicity of therapeutic drug monitoring. The purpose of this study was to examine the outcomes associated with IIV compared to CIV.
Methods
This was a retrospective study of patients who received vancomycin for MRSA bacteremia. The primary outcomes were the time to therapeutic goal and frequency of adverse drug reactions on IIV compared to CIV. Secondary outcomes evaluated all-cause readmission, relapse, and mortality 30 days after completion of therapy.
Results
Sixty-three patients were included. Significantly fewer patients were able to achieve a therapeutic goal on IIV compared to CIV (52.4% vs. 82.5%, p < 0.01). Patients on IIV took 3.6 days, on average, to reach the target goal, compared to 1.9 days when patients were switched to CIV (95% confidence interval, 0.48–3.04, p < 0.01). Six patients experienced adverse events on IIV, and 15 patients experienced adverse events on CIV (IIV 9.5%, CIV 23.8%, p = 0.035). One patient experienced relapse of infection, and six patients (9.5%) were readmitted 30 days after completion of therapy. There were no deaths in the cohort.
Conclusion
For MRSA bacteremia, CIV enabled patients to achieve the AUC/MIC goal significantly faster than when patients received IIV. Furthermore, patients who were unable to achieve a therapeutic trough on IIV became therapeutic once switched to CIV.
Details
- Title: Subtitle
- Retrospective review of intermittent and continuous infusion vancomycin for methicillin-resistant Staphylococcus aureus bacteremia
- Creators
- Diari Gilliam - University of New Mexico HospitalDominic Acosta - Presbyterian Healthcare ServicesMartha L. Carvour - University of Iowa Hospitals and ClinicsCarla Walraven - University of New Mexico Hospital
- Resource Type
- Journal article
- Publication Details
- European journal of clinical pharmacology, Vol.80(1), pp.75-81
- DOI
- 10.1007/s00228-023-03585-2
- PMID
- 37897529
- ISSN
- 0031-6970
- eISSN
- 1432-1041
- Language
- English
- Electronic publication date
- 10/28/2023
- Date published
- 01/2024
- Academic Unit
- Infectious Diseases; Epidemiology; Fraternal Order of Eagles Diabetes Research Center; Internal Medicine
- Record Identifier
- 9984501625002771
Metrics
27 Record Views